Iberia Pharmaceuticals to Open INR 70 Cr Manufacturing and R&D Facility in Haryana by 2026

The company aims to produce over 12 million units annually, catering to the Indian and international markets with a focus on dermatology, chronic care, and wellness.

Iberia Pharmaceuticals is set to establish a new 60,000 sq. ft. manufacturing and research facility in Jhajjar, Haryana, as part of its India expansion strategy.

The unit, scheduled to be operational by mid-2026, represents a capital investment of INR 70 crore and aligns with the government’s ‘Make in India’ initiative.

The upcoming facility will have advanced control systems and machinery to support large-scale commercial manufacturing. It is designed to meet international quality, compliance, and environmental sustainability standards.

The company aims to produce over 12 million units annually, catering to the Indian and international markets with a focus on dermatology, chronic care, and wellness.

“This new plant marks a major milestone in our growth journey,” said Nitin Jain, Founder of Iberia Pharmaceuticals. “By bringing global manufacturing quality to India, we are building trust, capacity, and a future where healthcare meets world-class standards. This facility is one of several strategic initiatives we are implementing to support rapid growth. We proudly support the Government of India’s vision of expanding access to high-quality, affordable healthcare solutions,” Jain added.

The facility will also feature R&D laboratories to track market trends, develop new formulations, and improve existing products. Iberia Pharmaceuticals will focus on vegan, high-performance, and pharmaceutical-grade nanotechnology-based therapeutic and skincare solutions.

Co-founder Saurav Ojha said, “At Iberia Pharmaceuticals, our purpose is clear—we want to deliver healthcare solutions that are precise, safe, and responsible. Our new advanced manufacturing and research facility stands as a symbol of that commitment. We are setting new benchmarks in dermatological excellence through nanotechnology and deep scientific research.”

Iberia’s current product portfolio includes brands such as Sesderma, Mediderma, Dermpix, Noreva, and Metacare, which serve dermatologists, wellness clinics, and consumers seeking science-backed skincare options.

Stay tuned for more such updates on Digital Health News